RecruitingNCT07819526

Acute Ischemic Stroke in Patients With Active Cancer

Clinical Characteristics and Stroke Recurrence in Patients With Acute Ischemic Stroke and Active Cancer: The CAT-AIS Multicenter Prospective Observational Study


Sponsor

Osaka University

Enrollment

500 participants

Start Date

Mar 1, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this multicenter prospective observational study, conducted at 24 hospitals in Japan, is to learn about recurrent ischemic stroke in people with active cancer who develop acute ischemic stroke. One of the main objectives is to evaluate how often ischemic stroke recurs during follow-up. The main questions this study aims to answer are: * How often does ischemic stroke recur within 3 months after the initial stroke? * Which clinical factors may be associated with recurrent ischemic stroke? * What other clinical outcomes occur during follow-up? Participants will receive medical care determined by their treating physicians. Researchers will collect information about participants' cancer, stroke characteristics, test results, treatments, recurrent ischemic stroke, and other clinical outcomes. Researchers will also explore whether clinical factors are associated with recurrent ischemic stroke and other outcomes. This study will not assign participants to a specific treatment.


Eligibility

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with active cancer and acute ichemic stroke. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

The Univeristy of Osaka

Suita, Osaka, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07819526


Related Trials